A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.


Journal

The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566

Informations de publication

Date de publication:
23 Nov 2023
Historique:
medline: 24 11 2023
pubmed: 23 11 2023
entrez: 23 11 2023
Statut: epublish

Résumé

BACKGROUND Hyperphosphatemia is a complication of chronic renal failure (CRF) due to reduction in the glomerular filtration rate. Lanthanum carbonate is a commonly used phosphate binder for patients with CRF and hyperphosphatemia, but has adverse effects if patients are not monitored. This report is of a 47-year-old man with hyperphosphatemia due to CRF treated with lanthanum carbonate tablets who presented acutely with partial large bowel obstruction. The incidence of lanthanum carbonate causing intestinal obstruction is rare, and few cases in the literature have described the course of the disease in detail. CASE REPORT A 47-year-old man diagnosed with diabetic nephropathy underwent hemodialysis treatment and was prescribed 0.5 g/day of chewable lanthanum carbonate tablets. After taking lanthanum carbonate for 5 months, the patient experienced symptoms of decreased bowel movements and exhaustion, which progressively worsened. Abdominal computed tomography (CT) revealed multiple hyperdensities in the large bowel, indicating the presence of lanthanum deposition. Lanthanum carbonate was promptly discontinued. After undergoing enema and catharsis treatment, the large bowel obstruction was relieved, and the hyperdensities in the abdominal CT disappeared. The colonoscopy and histologic examination revealed ulcerations and inflammatory changes in the large bowel mucosa. CONCLUSIONS This report highlights the rare association between the use of lanthanum carbonate tablets and intestinal obstruction. Healthcare providers should enhance their vigilance regarding lanthanum carbonate-induced serious gastrointestinal adverse reactions and actively seek to detect lanthanum deposition by abdominal CT or radiography (X-ray). After the occurrence of lanthanum deposition, drug withdrawal and promotion of defecation are primary treatment methods.

Identifiants

pubmed: 37994013
pii: 942113
doi: 10.12659/AJCR.942113
doi:

Substances chimiques

lanthanum carbonate 490D9F069T
Lanthanum 6I3K30563S
Tablets 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e942113

Auteurs

Qin Zhou (Q)

Department of Gastroenterology, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).

Mengchen Yu (M)

Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).

Xin Chang (X)

Department of Gastroenterology, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).

Shenglan Shang (S)

Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).

Min Li (M)

Department of Gastroenterology, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).

Weitian Xu (W)

Department of Gastroenterology, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH